Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

CompletedOBSERVATIONAL

Enrollment

2,101

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Multiple Sclerosis

Interventions

OTHER

Ofatunumab

All eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort

Trial Locations (1)

Novartis Investigative Site, East Hanover